Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur Neuropsychopharmacol. 2008 Oct;18(10):768-72. doi: 10.1016/j.euroneuro.2008.05.007. Epub 2008 Jul 9.

Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia.

Author information

  • 1Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Strasse 25, Germany. rainald.moessner@ukb.uni-bonn.de

Abstract

In recent years, evidence has been accumulating indicating a major role of glutamate in the pathogenesis and pathophysiology of schizophrenia. Of particular importance in this regard are the metabotropic glutamate receptors (GRM). Thus, a recently published trial of the amino acid analogue LY2140023, which exerts its effects through the activation of the glutamate receptors GRM3/GRM2, showed an improvement of positive and negative symptoms comparable to treatment with olanzapine. A functional variant of GRM3 has been described which modulates synaptic glutamate levels. We assessed whether this functional variant rs6465084 is related to schizophrenia in a large sample of patients and controls. We found an increased frequency of the A allele (p=0.027) and the AA genotype (p=0.024) in schizophrenia patients. Moreover, in an assessment of schizophrenia endophenotypes, patients of the AA genotype performed poorly in the digit symbol test, a measure of attention (p=0.008). Our results provide further evidence for the potential importance of the glutamate receptor GRM3 in schizophrenia, and indicate that the novel antipsychotic LY2140023 may actually be targeting a pathogenic pathway of schizophrenia.

PMID:
18614340
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk